GB2310801A - Process for removing an organic solvent from lactide-glycoside copolymer microspheres - Google Patents

Process for removing an organic solvent from lactide-glycoside copolymer microspheres Download PDF

Info

Publication number
GB2310801A
GB2310801A GB9704186A GB9704186A GB2310801A GB 2310801 A GB2310801 A GB 2310801A GB 9704186 A GB9704186 A GB 9704186A GB 9704186 A GB9704186 A GB 9704186A GB 2310801 A GB2310801 A GB 2310801A
Authority
GB
United Kingdom
Prior art keywords
microspheres
ethyl acetate
lactide
water
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9704186A
Other versions
GB9704186D0 (en
Inventor
Rey T Chern
James C Tang
Roger A Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608930.5A external-priority patent/GB9608930D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB9704186D0 publication Critical patent/GB9704186D0/en
Publication of GB2310801A publication Critical patent/GB2310801A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Description

TITLE OF THE INVENTION PROCESS FOR REMOVING ORGANIC PHASE SOLVENT FROM PLGA MICROSPHERES CONTAINING A LIPOPHILIC DRUG BACKGROUND OF THE INVENTION The present invention relates to a process of removing the organic solvent from PLGA microspheres. Micospheres made of poly(lactide-co-glycolide) have been widely studied for the delivery of drugs and biologicals. One of the most popular methods for preparing drug-containing microspheres involves the formation of an oil-in-water emulsion followed by solvent removal via an extraction/evaporation, henceforth referred to as the 'single emulsion process'. In this process, the suspension (after solvent extraction/evaporation and washing) is sometimes lyophilized with appropriate additives and packaged as a finished product. More often, wet microspheres are recovered from the suspension, dried and packaged.
Ordinarily an extended solvent extraction step followed by drying or other measures is required to provide PLGA microspheres which are suitable for use in pharmaceutical preparations. The present invention involves a minimum amount of organic solvent removal or extraction time, with up to about 95% removal occcuring essentially in a few minutes.
SUMMARY OF THE INVENTION In one aspect of the invention, a process for removing the organic phase solvent from poly(lactide-co-glycolide) microspheres containing a lipophilic drug compound is disclosed. The process compnses: forming poly(lactide-co-glycolide) microspheres in an ethyl acetate/water two phase system; emulsifying the two phase system at approximately a 1:1 to about 3:1 ratio of water to ethyl acetate continuously to form microspheres; and continuously introducing the emulsion into a water reservoir which is less than about 15-20 times the volume of the cumulative volume of the emulsion, effective for extracting the ethyl acetate from the microspheres.
In a further aspect of the invention, the process is as described above, wherein the water reservoir is effective for extracting up to about 95% of the ethyl acetate from the microspheres.
In yet another aspect of the invention, the process is as described above wherein the lipophilic drug compound is selected from the group consisting of: avermectins, milbemycins, nodulisporic acid and derivatives thereof, fipronil and steroids.
BRIEF DESCRIPTION OF THE DRAWINGS The invention is described in connection with the drawings appended hereto, of which: Figure I is the isothermal drying curve of a wet microsphere cake.
DETAILED DESCRIPTION OF THE INVENTION The following terms and definitions are applicable to the invention described herein unless otherwise indicated: As used herein, the term "poly(lactide-co-glycolide)" is used in the conventional sense to refer to: poly(glycolic acid), poly-d, l-lactic acid, poly-l-lactic acid, copolymers of glycolic acid, l-lactic acid and d,l-lactic acid. Commercial vendors include Medisorb Technologies International (MTI), Boeheringer Ingelheim and Birmingham Polymers.
Lipophilic drugs which are useful in the present invention include the following: avermectins, milbemycins, nodulisporic acid and derivatives thereof, fipronil and steroids. Generally, lipophilic drugs useful herein include those drugs which are water insoluble, and soluble in ethyl acetate and methylene chloride.
The emulsion that is continuously formed is introduced into a water reservoir as quickly as possible, preferably immediately. The water reservoir is up to about 15 to 20 times the cumulative volume of the emulsion.
Emulsifying agents which are useful in the present invention include: poly(vinyl alcohol), Tween 80, polysorbates and poloxamers.
The invention is further illustrated in connection with the following non-limiting example.
Materials PLGA (8515, iv= 0.689 dL/g) was purchased from MTI (Cincinnati, OH). Ethyl acetate and poly(vinyl alcohol) (88% hydrolyzed were supplied by Aldrich.
Procedure Avermectins (1 part) and PLGA (1 part) were dissolved in ethyl acetate (8 parts) to form the "organic phase". Poly(vinyl alcohol) was dissolved in water (0.5%) to form the "aqueous phase".
The two phases were mixed and emulsified continuously using an on-line static mixer at -2:1 ratio (aqueous:organic) and the emulsion was introduced immediately into a water reservoir under gentle agitation. The water reservoir is up to about 15-20 times the cumulative volume of the emulsion and is maintained at approximately 10 C.
Extraction rate of ethvl acetate Four batches of different sizes were made. The final ethyl acetate concentration in the water reservoir ranged from -1.6 to -5.0 wt%. As shown in Table 1, regardless of the batch size, approximately 90% of the solvent which was introduced via the oil-in-water emulsion was extracted into the water reservoir within 5 minutes. Longer extraction times removed marginally more solvent from the wet microspheres.
Since the yield of dry microspheres was greater than 95%, the wt% of ethyl acetate in the wet microspheres can be estimated from the data in Table 1. The estimates are shown in Table 2. Roughly 30 wt% of the wet microspheres is attributed to residual ethyl acetate.
Drying characteristics of wet microspheres The isothermal drying curve of the wet cake is illustrated in Figure 1. The TGA analysis was run at 35"C, with a dry-nitrogen flow rate of 10-20- cc/min. The volatile content of the microspheres can be lowered to less than 1 wt% in less than 15 min.
The total volatile content of the wet microspheres can also be determined from the drying curve. These data are summarized in Table 3. The volatile content does not vary much with extraction time.
Comparing the data in Tables 2 and 3 one also finds that more than two thirds of the volatile content of the wet microspheres is indeed solvent, the rest is water.
Table 1 Percent Solvent Extracted into Aqueous Phase After Dispersion
Batch ID Time, mien A B C D 5 91% 90% 90% 92% 15 88% 90% 90% 92% 60 87% 90% 96% Average Solvent wt% in the Aqueous Phase 9.95 1.61 4.36 5.04 Table 2 Solvent content of wet microspheres recovered by filtration (Calculated from solvent extraction data.)
Batch ID A B C D %Wt (wet-basis) 30 30 29 23 Table 3 Volatile content of wet microspheres recovered at various times after dispersion
Time, min 10 24 38 60 %Wt (wet-basis) ~ 33 ~ ~ 35 ~ 31 38 When ethyl acetate was used as the solvent for the preparation of microspheres in the 'single emulsion process', around 90% of the solvent was extracted into the water reservoir within 5 min.
Prolonging the extraction did not significantly increase the extent of solvent removal from the wet microspheres.
The high volatility of ethyl acetate, the small size of the microspheres (volume-average diameter in the range of 50 to 120 micron), and the favorable external mass transfer used allows nearly complete drying of the microspheres (to < 1 wt%) within 15 min at 35"C.
While certain preferred embodiments are described herein in detail, numerous alternative embodiments are contemplated as falling within the invention.

Claims (5)

WHAT IS CLAIMED IS:
1. A process for removing an organic phase solvent from poly(lactide-co-glycolide) microspheres containing a lipophilic drug compound, which comprises: combining poly(lactide-co-glycolide) and a lipophilic drug compound in an ethyl acetate/water two phase system; emulsifying the two phase system at approximately a 1:1 to about 3:1 ratio of water to ethyl acetate continuously to form microspheres; and continuously introducing the emulsion into a water reservoir which is less than about 15-20 times the volume of the cumulative volume of the emulsion, effective for extracting the ethyl acetate from the microspheres.
2. A process in accordance with claim 1 wherein the water reservoir is effective for extracting up to about 95% of the ethyl acetate from the microspheres.
3. A process in accordance with claim 1 wherein the two phase system is emulsified at approximately a 2:1 ratio of water to ethyl acetate.
4. A process in accordance with claim 2 wherein the lipophilic drug compound is selected from the group consisting of: avermectins, milbemycins, nodulisporic acid or a derivative thereof, fipronil and steroids.
5. A process in accordance with claim 1 wherein said emulsifying is comprised of adding an emulsifying agent selected from the group consisting of: poly(vinyl alcohol), Tween 80, polysorbates and poloxamers.
GB9704186A 1996-03-04 1997-02-28 Process for removing an organic solvent from lactide-glycoside copolymer microspheres Withdrawn GB2310801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1278096P 1996-03-04 1996-03-04
GBGB9608930.5A GB9608930D0 (en) 1996-04-29 1996-04-29 Process for removing organic phase solvent from PLGA microspheres containing a lipophilic drug

Publications (2)

Publication Number Publication Date
GB9704186D0 GB9704186D0 (en) 1997-04-16
GB2310801A true GB2310801A (en) 1997-09-10

Family

ID=26309232

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9704186A Withdrawn GB2310801A (en) 1996-03-04 1997-02-28 Process for removing an organic solvent from lactide-glycoside copolymer microspheres

Country Status (1)

Country Link
GB (1) GB2310801A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058112A1 (en) * 1998-05-13 1999-11-18 Microbiological Research Authority Improvements relating to encapsulation of bioactive agents
WO2000066087A2 (en) * 1999-05-03 2000-11-09 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
WO2002019988A2 (en) * 2000-09-05 2002-03-14 Roland Bodmeier Sustained release particle dispersion
EP1197207A2 (en) * 2000-10-10 2002-04-17 American Cyanamid Company Stable compositions for parenteral administration
EP1230338A1 (en) * 1999-11-19 2002-08-14 Zycos Inc. Continuous-flow method for preparing microparticles
US6667294B2 (en) 1995-11-09 2003-12-23 Microbiological Research Authority Microencapsulated DNA for vaccination and gene therapy
WO2007119028A2 (en) * 2006-04-19 2007-10-25 Galderma S.A. Composition including at least one aqueous phase and at least one fatty phase including ivermectin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011009A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
WO1995013799A1 (en) * 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011009A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
WO1995013799A1 (en) * 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Int. Symp. Controlled Bioact. Mater. Vol. 23 1996 Chern R T et. al. pages 363-364 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743444B2 (en) 1995-11-09 2004-06-01 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6667294B2 (en) 1995-11-09 2003-12-23 Microbiological Research Authority Microencapsulated DNA for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6309569B1 (en) 1998-05-13 2001-10-30 Microbiological Research Authority Encapsulation of bioactive agents
WO1999058112A1 (en) * 1998-05-13 1999-11-18 Microbiological Research Authority Improvements relating to encapsulation of bioactive agents
US6440493B1 (en) 1999-05-03 2002-08-27 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2000066087A2 (en) * 1999-05-03 2000-11-09 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2000066087A3 (en) * 1999-05-03 2001-06-21 Southern Biosystems Inc Emulsion-based processes for making microparticles
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
EP1230338A1 (en) * 1999-11-19 2002-08-14 Zycos Inc. Continuous-flow method for preparing microparticles
EP1230338A4 (en) * 1999-11-19 2004-03-31 Zycos Inc Continuous-flow method for preparing microparticles
WO2002019988A3 (en) * 2000-09-05 2002-06-27 Roland Bodmeier Sustained release particle dispersion
WO2002019988A2 (en) * 2000-09-05 2002-03-14 Roland Bodmeier Sustained release particle dispersion
EP1197207A3 (en) * 2000-10-10 2003-02-05 American Cyanamid Company Stable compositions for parenteral administration
EP1197207A2 (en) * 2000-10-10 2002-04-17 American Cyanamid Company Stable compositions for parenteral administration
WO2007119028A2 (en) * 2006-04-19 2007-10-25 Galderma S.A. Composition including at least one aqueous phase and at least one fatty phase including ivermectin
FR2900052A1 (en) * 2006-04-19 2007-10-26 Galderma Sa COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN
WO2007119028A3 (en) * 2006-04-19 2008-04-03 Galderma Sa Composition including at least one aqueous phase and at least one fatty phase including ivermectin
EP2374449A2 (en) * 2006-04-19 2011-10-12 Galderma S.A. Composition including at least one aqueous phase and at least one oil phase including ivermectin
EP2374449A3 (en) * 2006-04-19 2012-02-29 Galderma S.A. Composition including at least one aqueous phase and at least one oil phase including ivermectin
US8362069B2 (en) 2006-04-19 2013-01-29 Galderma S.A. Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds
US9592249B2 (en) 2006-04-19 2017-03-14 Galderma S.A. Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds

Also Published As

Publication number Publication date
GB9704186D0 (en) 1997-04-16

Similar Documents

Publication Publication Date Title
KR100211435B1 (en) Method for producing sustained release microsphere preparation
AU733199B2 (en) Microparticles
US5650173A (en) Preparation of biodegradable microparticles containing a biologically active agent
CA2074322C (en) A composition for the sustained and controlled release of medicamentous substances and a process for preparing the same
FI76493B (en) MIKROINKAPSLINGSFOERFARANDE.
EP1925297B2 (en) Method for preparing microparticles having a selected polymer molecular weight
US5503851A (en) Microencapsulation of water-soluble medicaments
FR2810885A1 (en) Sustained release microparticles and their preparation using a multi-emulsion process, for delivery of drugs for up to 6 months or longer
Soppimath et al. Ethyl acetate as a dispersing solvent in the production of poly (DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type
EP2327397A2 (en) Method for manufacturing sustained release microsphere by solvent flow evaporation method
PL212531B1 (en) Sustained-release composition and process for producing the same
EP1716847A1 (en) Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
EP3178471B1 (en) Preparation method of drug-containing sustained release microparticles
GB2310801A (en) Process for removing an organic solvent from lactide-glycoside copolymer microspheres
EP1210942B1 (en) Microparticles
WO1999033558A1 (en) Method for producing an aqueous colloidal dispersion of nanoparticles
CA2123481C (en) Process for the preparation of microballs and microballs thus obtained
CA2527994C (en) Process for producing microparticles
CN111643483B (en) Method for preparing galanthamine sustained-release microspheres
CN109939220A (en) Polypeptide microballoon and preparation method thereof with quick-release and slow release effect
WO2001002087A1 (en) Method for producing aqueous colloidal dispersions of nanoparticles
JP2006328060A (en) Bioabsorbable pharmaceutical formulation

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)